Tau Imaging in Alzheimer’s Disease Diagnosis and Clinical Trials
- First Online:
- Cite this article as:
- Brosch, J.R., Farlow, M.R., Risacher, S.L. et al. Neurotherapeutics (2017) 14: 62. doi:10.1007/s13311-016-0490-y
In vivo imaging of the tau protein has the potential to aid in quantitative diagnosis of Alzheimer’s disease, corroborate or dispute the amyloid hypothesis, and demonstrate biomarker engagement in clinical drug trials. A host of tau positron emission tomography agents have been designed, validated, and tested in humans. Several agents have characteristics approaching the ideal imaging tracer with some limitations, primarily regarding off-target binding. Dozens of clinical trials evaluating imaging techniques and several pharmaceutical trials have begun to integrate tau imaging into their protocols.
KeywordsAlzheimer’s disease Tau Tau imaging
|Funder Name||Grant Number||Funding Note|
|National Institute on Aging|